Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Novartis’ Rhapsido for CSU treatment
Novartis has obtained approval from the US Food and Drug Administration (FDA) for Rhapsido (remibrutinib) to treat adult patients suffering from chronic spontaneous urticaria (CSU).
Skin Inflammation
-
01 Oct 2025
-
27 Jun 2022
FDA accepts Emergent BioSolutions’ anthrax vaccine candidate for review
The US Food and Drug Administration (FDA) has agreed to review Emergent BioSolutions’ Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).